The novel C+/+/Tia1−/− model is also suited for testing the efficacy of therapeutic compounds aimed at the treatment of SMA and possibly other genetic diseases impacted by aberrant SMN and/or TIA1 expression. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.